Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical value of high expression level of CD71 in acute myeloid leukemia.

Neoplasma·2016
Same author

High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.

Indian journal of cancer·2016
Same author

Elimination of X-Ray Diffraction through Stimulated X-Ray Transmission.

Physical review letters·2016
Same author

Mapping the Interaction Anatomy of BmP02 on Kv1.3 Channel.

Scientific reports·2016
Same author

A proteomics analysis reveals that A2M might be regulated by STAT3 in persistent allergic rhinitis.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2016
Same author

Comparative Cost-Effectiveness of CT Perfusion for Selecting Stroke Patients for Thrombolysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016

Related Experiment Videos

Puerarin for acute ischaemic stroke.

Y Tan, M Liu, B Wu

    The Cochrane Database of Systematic Reviews
    |February 7, 2008
    PubMed
    Summary

    Puerarin, a herbal medicine, showed no significant difference in survival or dependency for acute ischaemic stroke patients in one trial. More high-quality research is needed to confirm its efficacy and safety.

    Area of Science:

    • Neurology
    • Pharmacology
    • Traditional Chinese Medicine

    Background:

    • Puerarin is a widely used herbal medicine in China for treating acute ischaemic stroke.
    • Its efficacy and safety in this context require rigorous scientific evaluation.

    Purpose of the Study:

    • To assess the efficacy and safety of puerarin in patients diagnosed with acute ischaemic stroke.
    • To synthesize evidence from available randomized controlled trials.

    Main Methods:

    • A comprehensive literature search was conducted across multiple databases including Cochrane, MEDLINE, EMBASE, AMED, and CBM-disc up to June/August 2006.
    • Inclusion criteria focused on randomized or quasi-randomized controlled trials comparing puerarin with placebo or open control in acute ischaemic stroke patients.
    • Data extraction and quality assessment were performed independently by two review authors.

    Related Experiment Videos

    Main Results:

    • One trial with 98 participants met the inclusion criteria.
    • No statistically significant difference was observed between the puerarin treatment group and the control group regarding death or dependency (OR 0.81; 95% CI 0.35 to 1.87).
    • No serious adverse effects were reported in the included trial.

    Conclusions:

    • Current evidence is insufficient to determine the effect of puerarin on survival or dependency in acute ischaemic stroke patients.
    • High-quality, large-scale randomized controlled trials are necessary to establish the efficacy and safety of puerarin.